SCHEMBL6947472

SCHEMBL6947472

CC(=O)O[C@@H]1[C@H](OC(C)=O)[C@H](OC(C)=O)CO[C@H]1n1cnc2cc(Cl)ccc21

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.45
GAA P10253 1/20 0.45
CYP3A4 P08684 1/20 0.42
CYP2C9 P11712 1/20 0.42
CYP2C19 P33261 1/20 0.42
CA1 P00915 4/20 0.41
CA2 P00918 4/20 0.41
CA9 Q16790 4/20 0.41
LMNA P02545 2/20 0.41
CA12 O43570 2/20 0.38
CA14 Q9ULX7 2/20 0.38
FGFR1 P11362 1/20 0.36
ALDH1A1 P00352 2/20 0.35
TP53 P04637 2/20 0.35
MAPT P10636 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
PLK1 P53350 1/20 0.34
GABRA1 P14867 1/20 0.34
GABRG2 P18507 1/20 0.34
GABRB3 P28472 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6952230 0.93 POLB (0.44) POLBGAACYP3A4CYP2C9CYP2C19
SCHEMBL7615007 0.87 POLB (0.44) POLBGAACYP3A4CYP2C9CYP2C19
SCHEMBL6957522 0.84 POLB (0.42) POLBGAACYP3A4CYP2C9CYP2C19
SCHEMBL6955468 0.84 POLB (0.42) POLBGAACYP3A4CYP2C9CYP2C19
SCHEMBL6952131 0.83 POLB (0.41) POLBGAACYP3A4CYP2C9CYP2C19
SCHEMBL6955512 0.83 POLB (0.41) POLBGAACYP3A4CYP2C9CYP2C19
SCHEMBL6945678 0.83 POLB (0.44) POLBGAACYP3A4CYP2C9CYP2C19
SCHEMBL6951505 0.82 POLB (0.41) POLBGAACYP3A4CYP2C9CYP2C19
SCHEMBL6947726 0.82 POLB (0.40) POLBGAACYP3A4CYP2C9CYP2C19
SCHEMBL7739892 0.81 TP53 (0.40) LMNAFGFR1ALDH1A1TP53MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0994890-B1 BENZIMIDAZOLE DERIVATIVES GLAXO GROUP LTD (GB) 2003-08-06 EP disclosed
US-6455507-B1 E.G., 2-BROMO-5,6-DICHLORO-1-BETA-D-RIBOPYRANOSYL-1H-BENZIMIDAZOLE; VIRICIDES, ESPECIALLY INFECTIONS OF HERPES AND CYTOMEGALO VIRUSES SMITHKLINE BEECHAM CORPORATION 2002-09-24 US disclosed
US-20020094963-A1 BENZIMIDAZOLE DERIVATIVES GLAXO WELLCOME INC. 2002-07-18 US disclosed
EP-0994890-A2 BENZIMIDAZOLE DERIVATIVES GLAXO GROUP LIMITED (GB) 2000-04-26 EP disclosed
WO-1998056761-A2 BENZIMIDAZOLE DERIVATIVES GLAXO GROUP LIMITED (GB) 1998-12-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020094963-A1 BENZIMIDAZOLE DERIVATIVES ZC3HAV1, BRPF3, BRD3 POLB 1342/4885GAA 235/4885CYP3A4 69/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.